File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chemotherapy of tuberculosis in Hong Kong: a consensus statement

TitleChemotherapy of tuberculosis in Hong Kong: a consensus statement
Authors
KeywordsAnititubercular agents
Drug therapy, combination
Hong Kong
Tuberculosis/drug therapy
Issue Date1998
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org.hk
Citation
Hong Kong Medical Journal, 1998, v. 4 n. 3, p. 315-320 How to Cite?
AbstractThis consensus statement is prepared primarily as a concise reference for tuberculosis chemotherapy in Hong Kong. Treatment should be tailored to patients individually, expert advice should be sought when necessary, and 'directly observed treatment' should be used where possible. A 6-month regimen is recommended as the initial treatment of uncomplicated pulmonary tuberculosis and a 9-month regimen is recommended for retreatment. Patients with disease that is resistant to isoniazid or rifampicin may require modified regimens. Multidrug-resistant tuberculosis should be managed in specialised centres, using multiple drugs as guided by in vitro susceptibility tests. Recommended regimens to treat extrapulmonary tuberculosis are based on limited current evidence, although shorter regimens may be acceptable when better evidence emerges. A longer duration of treatment is required for diabetic, immuno-compromised, or silicotic patients. During pregnancy, streptomycin should be avoided; the safety profiles of second-line drugs have not yet been ascertained. Hepatotoxic drugs should be used with caution in patients with liver dysfunction, and extra caution and dosage reductions are required if streptomycin and ethambutol are used in patients with renal impairment.
Persistent Identifierhttp://hdl.handle.net/10722/45072
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorLam, WKen_HK
dc.contributor.authorLeung, CCen_HK
dc.contributor.authorChan, CKen_HK
dc.contributor.authorChang, KCen_HK
dc.contributor.authorChen, NKen_HK
dc.contributor.authorYew, WWen_HK
dc.contributor.authorChan, YCen_HK
dc.contributor.authorLam, CWen_HK
dc.contributor.authorChan, KSen_HK
dc.contributor.authorYu, WCen_HK
dc.contributor.authorChan, HSen_HK
dc.contributor.authorYung, WHen_HK
dc.contributor.authorYam, YCen_HK
dc.contributor.authorTam, CYen_HK
dc.contributor.authorLai, KWen_HK
dc.date.accessioned2007-10-30T06:16:51Z-
dc.date.available2007-10-30T06:16:51Z-
dc.date.issued1998en_HK
dc.identifier.citationHong Kong Medical Journal, 1998, v. 4 n. 3, p. 315-320en_HK
dc.identifier.issn1024-2708en_HK
dc.identifier.urihttp://hdl.handle.net/10722/45072-
dc.description.abstractThis consensus statement is prepared primarily as a concise reference for tuberculosis chemotherapy in Hong Kong. Treatment should be tailored to patients individually, expert advice should be sought when necessary, and 'directly observed treatment' should be used where possible. A 6-month regimen is recommended as the initial treatment of uncomplicated pulmonary tuberculosis and a 9-month regimen is recommended for retreatment. Patients with disease that is resistant to isoniazid or rifampicin may require modified regimens. Multidrug-resistant tuberculosis should be managed in specialised centres, using multiple drugs as guided by in vitro susceptibility tests. Recommended regimens to treat extrapulmonary tuberculosis are based on limited current evidence, although shorter regimens may be acceptable when better evidence emerges. A longer duration of treatment is required for diabetic, immuno-compromised, or silicotic patients. During pregnancy, streptomycin should be avoided; the safety profiles of second-line drugs have not yet been ascertained. Hepatotoxic drugs should be used with caution in patients with liver dysfunction, and extra caution and dosage reductions are required if streptomycin and ethambutol are used in patients with renal impairment.en_HK
dc.format.extent34269 bytes-
dc.format.extent18665 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org.hken_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectAnititubercular agentsen_HK
dc.subjectDrug therapy, combinationen_HK
dc.subjectHong Kongen_HK
dc.subjectTuberculosis/drug therapyen_HK
dc.titleChemotherapy of tuberculosis in Hong Kong: a consensus statementen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1024-2708&volume=4&issue=3&spage=315&epage=320&date=1998&atitle=Chemotherapy+of+tuberculosis+in+Hong+Kong:+a+consensus+statementen_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.pmid11830690en_HK
dc.identifier.scopuseid_2-s2.0-0031724096-
dc.identifier.hkuros41304-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats